Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ResMed (RMD)

ResMed to sell MatrixCare unit to Frazier Healthcare for $490 million

Neutral Impact 4 of 5 m&a Written later

ResMed agreed on June 30, 2026 to sell its MatrixCare business to private equity firm Frazier Healthcare Partners for $490 million in cash, subject to closing adjustments. The company plans to use the proceeds to return capital to shareholders, including an accelerated share repurchase, and for general corporate purposes. The filing reiterates ResMed's fiscal 2026 outlook and says the full fiscal 2027 outlook will be given on August 6, 2026.

Key points

  • Buyer is Frazier Healthcare Partners; price is $490 million all-cash, subject to certain closing adjustments.
  • Deal is expected to close in the first quarter of fiscal 2027, subject to regulatory approvals and customary conditions.
  • MatrixCare had approximately $220 million of revenue and $55 million of non-GAAP operating profit in fiscal 2026, based on preliminary results.
  • Recently completed Noctrix acquisition is expected to add about $30 million of fiscal 2027 revenue and reduce non-GAAP diluted EPS by about $0.20.

The filing

CompanyResMed (RMD)
Form8-K, current report
Filed with the SECJul 7, 2026, 5:24 PM ET
Accession number0001193125-26-297658

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:30 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.